

Rheumatoid arthritic... : investment in Plaquenil provides for the RA.

Contributors

Bayer Products

Publication/Creation

Surbiton-Upon-Thames, Surrey : Bayer Products, 1961.

Persistent URL

<https://wellcomecollection.org/works/znd74w5q>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

rheumatoid arthritic . . .



investment in
plaquenil Regd.
provides for the
R
A

MAXIMUM BENEFIT
AT MINIMUM RISK

70% of rheumatoid patients are showing major improvement with anti-malarial drugs. Plaquenil not only produces this improvement, but when compared with other potent anti-rheumatic drugs, demonstrates the lowest incidence of side effects.

Mobility improves with Plaquenil.

Hydroxychloroquine sulphate 200 mg.
Basic N.H.S. cost of average week's treatment
(2 tablets daily): 6/4d.

BAYER PRODUCTS, Division of Winthrop Group Ltd.,
Surbiton-upon-Thames, Surrey.

PLAQUENIL Regd.

MAY 1961